<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403829</url>
  </required_header>
  <id_info>
    <org_study_id>2017-NPC001</org_study_id>
    <nct_id>NCT03403829</nct_id>
  </id_info>
  <brief_title>Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage</brief_title>
  <official_title>A Phase III Randomized Trial of Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to now, IMRT has largely improved the local control of locally advanced nasopharyngeal
      carcinoma (NPC), leaves the distant metastasis as the main treatment failure modality of
      patients with bulky lymph nodes (especially N3 stage). Although concurrent chemoradiotherapy
      (CCRT) continues to stand as the standard treatment of these patients, the role of adjuvant
      chemotherapy remains controversial due to its relatively severe toxicities and inferior
      compliance. However, our retrospective study of 2D-RT and IMRT era had proved adjuvant
      chemotherapy played key role in N3 NPC patients in terms of reducing distant metastasis and
      improving overall survival. Maintenance chemotherapy of gemicitabine single drug is promising
      with adequate efficacy and moderate toxicities. So we aim to conduct &quot;A Phase III Randomized
      Trial of Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients
      of N3 Stage&quot; to evaluate the effectiveness and compliance of gemicitabine as maintenance
      chemotherapy in N3 nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to conduct &quot;A Phase III Randomized Trial of Maintenance Chemotherapy in
      High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage&quot; to evaluate the
      effectiveness and compliance of gemicitabine as maintenance chemotherapy in N3 nasopharyngeal
      carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distant metastatic free survival</measure>
    <time_frame>5 year</time_frame>
    <description>from enrollment to distant metastatis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>maintenance arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine maintenance treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>observe and follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine maintenance chemotherapy</description>
    <arm_group_label>maintenance arm</arm_group_label>
    <other_name>standard chemoradiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard chemoradiotherapy</intervention_name>
    <description>standard chemoradiotherapy</description>
    <arm_group_label>maintenance arm</arm_group_label>
    <arm_group_label>control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AJCC/UICC 8th edition N3 nasopharyngeal carcinoma

          -  Pathology: WHO II/II

          -  No prior anti-tumor treatment

          -  Age 18-60

          -  KPSâ‰¥70

          -  Adequate blood supply

          -  Informed consent obtained

        Exclusion Criteria:

          -  Pathology: WHO I

          -  Pregnant

          -  Combined with other malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaosu Hu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai cancer centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaosu Hu</last_name>
    <phone>862164175590</phone>
    <email>hucsu62@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Centre</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaosu Hu</last_name>
      <phone>+8674175590</phone>
      <phone_ext>1400</phone_ext>
      <email>hucsu62@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chaosu Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

